Archive for the ‘HGH Publications’ Category

In this section you will find the latest human growth hormone publications, research and medical papers concerning HGH.

You can view all the latest medical news and research papers conducted on human growth hormone.

Metabolic Benefits Seen with Growth Hormone Replacement

By Nancy Walsh, Contributing Writer, MedPage Today

Published: June 20, 2010

Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and

Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

Action Points

Explain to interested patients that for people with growth hormone deficiency, studies suggest that recombinant growth hormone therapy can have various metabolic benefits, such as increasing levels of “good” HDL cholesterol.

Note that these studies were published as posters and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Adults with growth hormone deficiency treated with recombinant human growth hormone (rhGH) therapy experience a variety of metabolic benefits, researchers reported here.

For example, among a group of 70 growth hormone deficient patients treated for three years with rhGH, levels of so-called “good” high density lipoprotein (HDL) cholesterol rose from a baseline mean level of 45 mg/dL to 56 mg/dL (P<0.001), according to Victor Oguntolu, MD, and colleagues from King’s College University Hospital, London.

“Adult growth hormone deficiency is a well-recognized syndrome characterized by dyslipidemia, changes in body fat distribution, and premature atherosclerosis,” he said in a poster session at the annual meeting of the Endocrine Society here.

Growth hormone deficiency usually results from tumor-induced damage to the pituitary gland, and patients often also experience decreases in bone mass and insulin resistance.

The link between growth hormone deficiency and elevated levels of harmful low density lipoprotein (LDL) cholesterol has been widely recognized, but the effects of growth hormone treatment on HDL have not previously been explored.

To analyze the possible effects on HDL, the King’s College researchers conducted a retrospective study of 32 men and 38 women who had completed at least three years of treatment with rhGH.

All patients had peak growth hormone levels as measured during an insulin or glucagon stimulation test of below 9 mU/L.

Therapy with rhGH was initiated at a dose of 0.3 mg/day and increased to 0.5 mg/day in the first three months.

The dose of rhGH was further titrated in the first year with the goal of achieving a target insulin-like growth factor (IGF)-1 level between the age-specific mean and the upper limit of reference.

Significant improvements became evident after six months of treatment with rhGH, Oguntolu told MedPage Today.

At six months, the following were lipid levels compared with those at baseline:

• Total cholesterol, 224 mg/dL versus 234 mg/dL

• LDL, 131 mg/dL versus 139 mg/dL

• HDL, 50 mg/dL versus 45 mg/dL

• Triglycerides, 205 mg/dL versus 230 mg/dLAside

Aside from the significant improvements in HDL, further reductions in other lipids were seen at three years:

• Total cholesterol, 196 mg/dL, P<0.0001

• LDL, 101 mg/dL, P<0.001

• Triglycerides, 175 mg/dL, P<0.001

“Most previous studies have only followed patients up to 24 months, and it’s after 24 months that HDL starts to change, whether patients are taking statins or not,” Oguntolu said.

A second poster at the meeting addressed the influence of growth hormone replacement therapy among adults on the development of diabetes.

Among 5,143 patients treated for a mean of 3.9 years with rhGH, diabetes developed in 523, according to Anton Luger, MD, of the University of Vienna, and colleagues.

The incidence was 2.6 per 100 patient-years, a rate six times higher than what was expected in a reference population in southern Sweden.

However, these data are “reassuring,” Luger told MedPage Today, because the patients who developed diabetes were older, had a worse lipid profile, and higher body mass index (BMI) and blood pressure than those who remained normoglycemic during rhGH therapy:

• Age: 52.7 years versus 48.5 years, P<0.0001

• BMI: 31.6 kg/m2 versus 28.9 kg/m2, P<0.0001

• HDL: 41 mg/dL versus 48.3 mg/dL, P<0.0001

• Systolic blood pressure: 132.9 mm Hg versus 127.9 mm Hg, P<0.0001

• Diastolic blood pressure: 81.1 mm Hg versus 79.6 mm Hg, P<0.0001

And although the observed-to-expected ratio for diabetes was elevated in patients receiving rhGH, the incidence fell with increasing duration of treatment and was not associated with IGF-1 standard deviation scores or growth hormone dose, Luger added.

Nonetheless, hormone deficient patients, especially those with an adverse risk profile, should be followed carefully, he cautioned.

Primary source: The Endocrine Society

Source reference: Oguntolu V, et al “The effect of a 3-year growth hormone replacement on lipid profile of adults with growth hormone deficiency” ENDO 2010; Poster 1-267.

Additional source: The Endocrine Society

Source reference: Luger A, et al “Incidence of diabetes mellitus in growth hormone (GH) deficient patients during GH replacement therapy — an analysis of KIMS (Pfizer International Metabolic Database)” ENDO 2010; Poster 1-270.

Tags: growth hormone, growth hormone replacement

Growth Hormone Treatment Study Shows it Improves Sports Performance

The latest research and researchers in Australia have just published medical data showing a positive and benefical influence of human growth hormone treatment on sprint capabilities and abilities in athletes. The impact was even more evident when androgenic hormone or testosterone was co-administered.

Athletes taking human GH experienced a 0.4-second improvement in a 10-second sprint.

“This improvement could turn the last place finished in the Olympic finals into a gold medal winner,” Ken Ho, MD, head of the department of endocrinology at St. Vincent’s Hospital in Sydney, said in a press release.

These information justify Gh staying a banned substance, even though evidence of its performance-enhancing effect has been poor so far, in accordance to the researchers.

The research incorporated 96 recreationally trained sports athletes, which include 63 men ). Dr. Ho and colleagues randomly assigned athletes to a placebo, Gh 2 mg per day, testosterone 250 mg per week for men only, or combined Growth hormone and testosterone.

Spring capability significant upgraded for males and women who received human GH (combined improvement, 0.71 kJ; 95% CI, 0.1-1.3), for a relative increase of 3.9%.

Males designated to Gh and testosterone experienced increased improvements in sprint capacity (0.71 kJ; 95% CI, 0.5-3.0), equal to a relative increase of 8.3%.

In a 6-week follow-up, spring ability changes were not maintained, in accordance to the scientists.

Combination therapy in males was additionally connected with significantly decreased fat mass and increased lean body mass through an improvement in extracellular water and body cell mass.

The research workers observed no substantial changes in other overall performance measures such as endurance and stamina, strength and power.

Runners in all treatment organizations reported inflammation, joint/muscle pain, paresthesias and acne; however, negative consequences were more repeated in those assigned to Gh, particularly joint pain.

“In our study, we used doses of GH on the low end of what is believed to be abused in sports,” Ho said. “For that reason, we think that the real effects of GH could be far greater than what is reported in our study. Equally, the side effects could be much more serious, as well.”

The analysts recommended future research to address aerobic overall performance, energy and power responses to Gh therapy at higher doses for extended durations and an examination of the biochemical components that trigger Gh’s growth of anaerobic capacity.

Meinhardt U. Ann Intern Med. 2010;152:568-577.

Tags: Growth hormone treatment, HGH products

HGH Improves Lipid Profile, Human Growth Hormone Research

Low-dose GH Replacement

Improves the Adverse Lipid Profile Associatedwith the Adult GH Deficiency Syndrome

Abstract

Objective: Adult growth hormone deficiency (AGHD) is associated with an adverse lipid profile. The majority of previous studies of GH replacement have used supraphysiological doses and reported favourable changes in the lipid profile. Whether this beneficial effect is the result of pharmacological GH therapy, or occurs in response to low-dose GH replacement aimed at normalization of the serum IGF-I, has not been fully elucidated.

Study Design: We studied 67 patients with GH deficiency using a low-dose individualized GH replacement regimen. GH was commenced at a dose of 0.27 mg/day and the GH dose titrated until the serum IGF-I was normalized. Serum lipids were assessed at baseline, 12 and 24 months. RESULTS A reduction in total cholesterol (TC) was observed at 12 (6.01 vs. 5.77 mmol, P= 0.04) and 24 months (6.01 vs. 5.56, P= 0.09). The reduction in LDLC failed to reach significance at 12 months (3.97 vs. 3.8, P = 0.09), but was significant at 24 months (3.97 vs. 3.50, P = 0.02). Levels of HDLC did not change significantly at 12 or 24 months.

Significant improvements in the TC/HDLC ratio were observed at both 12 (5.68 vs. 5.29, P= 0.01) and 24 months (5.68 vs. 4.86, P= 0.007). A significant fall in triglycerides (TG) was present at 12 months (2.07 vs. 1.83, P= 0.01), and was maintained at 24 months, but was no longer significant (2.07 vs. 1.89, P = 0.28).

At 12 months there was no correlation between improvements in lipid parameters and either the change in IGF-I SD score or the GH dose. Using multivariate analysis the change in TC, LDLC and theTC/HDLC ratio with 12 months GH replacement were determined by the baseline TC, LDLC and TC/ HDLC levels (R2 = 0.18, P= 0.004; R2 = 0.20, P= 0.006; and R2 = 0.33, P< 0.0001), respectively.

Conclusions: Low-dose individualized GH replacement aimed at normalization of the serum IGF-I is associated with significant improvements in TC, LDLC, TGs and the TC/HDLC ratio. The greatest improvements are observed in patients with the most adverse lipid profiles at baseline. Improvements are independent of changes in the IGF-I SDS and GH dose.

Source

http://cat.inist.fr/?aModele=afficheN&cpsidt=13777990

Email
Name
City
Country